biostudies-literatureUnknown24(3)Gubareva LVThe anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4-10-fold reduced susceptibility to baloxavir.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC6344838biostudies-literatureAssessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.PMC6344838Patel MCWentworth DEBarnes JMishin VPNguyen HTFry AMGubareva LVSinner MKatz JMChesnokov AReid HSpencer SGarten RCampbell APDe La Cruz JfalseAssessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4-10-fold reduced susceptibility to baloxavir.2019-01-01T00:00:00Z2019 Jan2025-04-25T23:29:02.113Z2019-03-26T22:53:12ZS-EPMC63448383067014410.2807/1560-7917.ES.2019.24.3.1800666